Masthead Logo
Section of Diabetes, Endocrinology and
Metabolism

eCommons@AKU
Department of Medicine

June 2017

Vitamin-D Toxicity And Other Non-Malignant
Causes Of Hypercalcemia: A Retrospective Study
At A Tertiary Care Hospital In Pakistan
Muhammad Naeem Khan
Liaquat National Hospital and Medical College, Karachi

Qamar Masood
Aga Khan University, qamar.masood@aku.edu

Mohammad Arsalan Siddiqui
Dow Medical College Karachi-Pakistan

Sabahat Naz
Aga Khan University, sabahat.naz@aku.edu

Najmul Islam
Aga Khan University, najmul.islam@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_med_diabet_endocrinol_metab
Part of the Endocrinology, Diabetes, and Metabolism Commons
Recommended Citation
Khan, M. N., Masood, Q., Siddiqui, M. A., Naz, S., Islam, N. (2017). Vitamin-D Toxicity And Other Non-Malignant Causes Of
Hypercalcemia: A Retrospective Study At A Tertiary Care Hospital In Pakistan. JAMC: Journal of Ayub Medical College, Abbottabad.,
29(3), 436-440.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_diabet_endocrinol_metab/78

J Ayub Med Coll Abbottabad 2017;29(3)

ORIGINAL ARTICLE

VITAMIN-D TOXICITY AND OTHER NON-MALIGNANT CAUSES OF
HYPERCALCEMIA: A RETROSPECTIVE STUDY AT A TERTIARY
CARE HOSPITAL IN PAKISTAN
Muhammad Naeem Khan, Muhammad Qamar Masood*, Mohammad Arsalan Siddiqui**,
Sabahat Naz*, Najmul Islam*
Department Diabetes Endocrinology & Metabolism, Liaquat National Hospital and Medical College, Karachi, *Aga Khan University Hospital
Karachi, **Dow Medical College Karachi-Pakistan

Background: Hypercalcemia is a common clinical problem; primary hyperparathyroidism and
malignancy is commonest causes of hypercalcemia. Aetiology of hypercalcemia are changing,
causes that were diseases of the past like Vitamin-D toxicity and milk alkali syndrome are
observed more often. Vitamin-D deficiency is an important problem and overzealous replacement
of Vitamin-D has been observed, suspected to cause toxicity. Method: This was a retrospective
review of patients admitted at the Aga Khan University Hospital from January 2008 to December
2013 with hypercalcemia. We reviewed the electronic health records for laboratory and
radiological studies, and discharge summaries to establish the cause of hypercalcemia. Patients
with solid tumour malignancy were excluded from the analysis. The treatment records and hospital
course of patients diagnosed with Vitamin-D toxicity were also reviewed. Results: Primary
hyperparathyroidism was the most common cause of hypercalcemia comprising 41 (28.2 %)
patients. Vitamin-D toxicity was present in 25 (17.3%) and probable Vitamin-D toxicity 11 (7.6
%) inpatients. Vitamin-D toxicity and probable Vitamin-D toxicity together comprised 36 (24.8%)
cases. Other causes of hypercalcemia included multiple myeloma 18 (12.4%) patients, tuberculosis
6 (4.1%) patients, chronic kidney disease6 (4.1%) cases, sarcoidosis 4 (2.7%) and lymphoma 3
(2.0%) patients. In 29(20%) patients a cause of hypercalcemia could not be determined and were
labelled as undiagnosed cases. Conclusion: Vitamin-D toxicity was the second commonest cause
of hypercalcemia after primary hyperparathyroidism. Knowledge of the prevalent and emerging
causes of hypercalcemia is important for prompt diagnosis and treatment.
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INTRODUCTION
Hypocalcaemia is a common clinical problem;
primary hyperparathyroidism (HPT) and malignancy
are commonest causes of hypercalcemia.1,2
Frequency of hypercalcemia in different disease
entities has been described. However recent literature
is lacking about frequency of different aetiologies
when patient presents primarily with hypercalcemia.
Study in the military veteran’s population in the
United States showed that 54% of the patients had
hypercalcemia attributable to causes other than
malignant disease or HPT.3
Studies in our region are limited to the
frequency of hypercalcemia occurring in specific
diseases. The spectrum of the aetiology of
hypercalcemia may be changing and the causes that
were diseases of the past like Vitamin-D toxicity
(VDT) and milk alkali syndrome; are observed more
often. The only study highlighting the frequency of
hypercalcemia in Pakistan is limited to patients with
multiple myeloma.4
Vitamin-D deficiency (VDD) has resurfaced
as an important public health problem; and at the
same time overzealous replacement of Vitamin-D has
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also been observed. Intramuscular Vitamin-D
preparations, containing 200,000 and 600,000 IU
of Vitamin-D3 are commonly used in Pakistan.
Guidelines on these vitamin preparations are
lacking. Practices among physicians vary widely,
conservative being using 600,000 IU IM or orally
every 3 months to very aggressive regimen of
600,000 IU weekly for up to 12 weeks.5 Review of
laboratory data from our centre is suggesting
shifting
of
Vitamin-D
deficiency
to
hypervitaminosis D and toxicity.6 Sporadic cases
of VDT have been noticed by the physician
community. However, there is no published
literature to evaluate the magnitude of VDT.
Bansal et al from India reported a case of VitaminD toxicity in a patient who had received 10
injections of Vitamin-D3, 600,000IU after the knee
surgery.7 Hypercalcemia has also been reported
because of excess ingestion of Vitamin-D in
dietary supplements.8,10 In two cases, the amounts
of Vitamin-D found in vitamin preparations were
much higher than listed by the manufacturer.9,10
Hypercalcemia presents as a diagnostic
challenge except in patients with solid tumour
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malignancy where it is a late finding and
underlying disease is often known.11 Knowledge of
the commonly occurring causes will help in
reaching the diagnosis promptly and in a costeffective manner. It can identify preventable
causes and may demand change in replacement
practices of Vitamin-D.

MATERIAL AND METHODS
This study was a retrospective analysis examining
the causes of hypercalcemia in patients without
solid tumour malignancy. A list of patients,
admitted with hypercalcemia from January 2008 to
December 2013 at the Aga Khan University
Hospital (AKUH) was generated by Health
Information Management Systems department.
Patients admitted under the care of an oncologist
were excluded from the search. The study was
approved by the ethics review committee of
AKUH.
The electronic health records were
reviewed for laboratory studies including
histopathology, radiological investigations and
discharge summaries to establish the cause of
hypercalcemia. Treatment records and hospital
course of patients diagnosed with VDT were
reviewed.
Hypercalcemia was labelled if there were
2 or more readings of serum calcium (Ca) or
albumin corrected calcium level above 10.2 mg/dl.
Primary HPT was diagnosed if there was
unequivocal
hypercalcemia
and
high
or
inappropriately normal intact parathyroid hormone
(iPTH) levels. VDT was diagnosed in patients with
hypercalcemia and 25-hydroxy Vitamin-D (25OHD) >150 ng/ml and low iPTH. Probable
Vitamin-D toxicity (probable VDT) was labelled in
patients with high Ca, suppressed iPTH and 25OHD level between 80–149 ng/ml and no other
cause of hypercalcemia. The diagnosis of multiple
myeloma was based on immunofixation or bone
marrow aspiration studies. The diagnoses of
tuberculosis, sarcoidosis and lymphoma were made
on review of histopathology, microbiology and
radiological
studies. The
aetiology once
established was reconfirmed by a second
researcher. In patients where review of medical
records did not reveal any diagnosis or workup
was incomplete were referred to as undiagnosed
cases.
Data was collected on patient demographics,
age, sex, serum Ca, serum phosphorus, serum iPTH,
25-OHD, urine creatinine, urine Ca, blood urea
nitrogen, clinical notes, surgical interventions,
pathology reports, and radiologic reports. Complete
details were recorded on a proforma.

All analyses were conducted by using the SPSS-19.0.
A descriptive analysis was done and features were
presented as mean±standard deviation for
quantitative variables and number (Percentage) for
qualitative variables.

RESULTS
Health information system generated a list of 322
patients with hypercalcemia. Review of the records
revealed that 36 patients had normal serum Ca levels
and 28 patients had transient hypercalcemia which
did not recur during hospital stay. Out of remaining
258 patients 113 patients had solid tumour and were
excluded from further analysis.
The electronic health records of remaining
145 patients were analysed to establish the aetiology
of hypercalcemia. This included 100 females (69%)
and 45 males (31%), with the mean age of
64.5±13.16 and mean Ca13.16±1.88 mg/dl.
HPT was the most common cause of
hypercalcemia comprising 41 (28.3 %) patients. In
these patients female to male ratio was 3.5:1 with
mean PTH level of 638.1±762.1 pg/ml, mean calcium
level 12.8±2.2 mg/dl.
Twenty-five (17.3%) had VDT; female to
male ratio in these patients was 2.1:1. The mean Ca
was 13.5±1.6 mg/dl. The mean 25-OHD level in four
patients was 368 ng/ml and in remaining 21 patients
it was reported as >150 ng/ml. Drowsiness was the
most common clinical presentation. The average
hospital stay was 7 days and 2 patients died during
hospitalization. The cause of death in one patient was
aspiration pneumonia and Non-ST elevation
myocardial infarction developed during hospital
course. The other patient had prolonged hospital stay
in two hospitals and had infected bedsores with
resultant septic shock as the cause of death. These
patients underwent extensive work up for drowsiness
including magnetic resonance imaging (MRI) brain,
cerebrospinal
fluid
analysis
and
electroencephalogram. The diagnosis was evident by
the 3rd day of hospital stay and required multiple tests
including
iPTH,
25-OHD,
serum
protein
electrophoresis, and angiotensin converting enzyme
levels in some cases. History of administration of
multiple injections of high doses (600,000 units) of
Vitamin-D3 was available in half of the patients. It
was prescribed for osteoporosis; osteoporosis related
fractures and generalized body pain. Hypercalcemia
was managed with administration of intravenous
normal saline, furosemide and pamidronate.
Subcutaneous calcitonin and oral prednisolone was
used in some cases.
The hypercalcemia was
corrected after 3 days of the administration of
pamidronate. The dose ranged from 30 to 90 mg. One
patient needed a second dose of pamidronate.
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In addition, 11 (7.6 %) patients had probable VDT.
Female to male ratio was 2.6:1. Mean 25-OHD level
was 92.7±16.1 ng/ml and mean Ca was 12.5±1.8
mg/dl. These patients had similar clinical
presentation and clinical course. One patient died in
this group, who was intubated because of low
conscious level secondary to hypercalcemia, had
prolonged hospital stay and multiple hospital
acquired infections.
Other causes of hypercalcemia included
multiple myeloma 18 (12.4%) patients, tuberculosis 6
(4.1%) patients, Chronic kidney disease 6 (4.1%)
cases, sarcoidosis 4 (2.7%) and lymphoma 3 (2.0%)
patients. In 29 (20%) patients a cause of

hypercalcemia could not be ascertained and were
labelled as undiagnosed cases. These patients had a
PTH independent cause of hypercalcemia. However
further workup was not available to reach to a
definitive
diagnosis.
In
one
patient
paraphenylenediamine poisoning was the cause of
hypercalcemia. The frequencies of different causes
with relative gender distribution are shown in table-1.
VDT and probable VDT together comprised
36 (24.8%) of the cases and one patient with HPT
had 25-OHD in toxic range. Table-2 mentions the
mean values of Ca, PTH and 25-OHD in various
causes of hypercalcemia.

Table-1: Frequency and gender distribution of different causes of hypercalcemia
Hyperparathyroidism
Undiagnosed cases
Vitamin-D toxicity
Multiple myeloma
Probable Vitamin-D toxicity
Tuberculosis
Chronic kidney disease
Sarcoidosis
Lymphoma
Hyperparathyroidism with Vitamin-D toxicity
Miscellaneous

Male
45 (31%)
9 (20)
8 (17.8)
8 (17.8)
7 (15.6)
3 (6.7)
4 (8.9)
3 (6.7)
1 (2.2)
2 (4.)
0 (0)
0 (0)

Female
100 (69%)
32 (32)
21 (21)
17 (17)
11 (11)
8 (8)
2 (2)
3 (3)
3 (3)
1 (1)
1 (1)
1 (1)

Total
145
41 (28.3)
29 (20)
25 (17.2)
18 (12.4)
11 (7.6)
6 (4.1)
6 (4.1)
4 (2.8)
3 (2.1)
1 (0.7)
1 (0.7)

Table-2: Mean values of PTH, Vitamin-D and Calcium
Total (n=145)
Hyperparathyroidism (n=41)
Vitamin-D toxicity (n=25)
Probable Vitamin-D toxicity (n=11)
Undiagnosed cases (n=29)
Multiple myeloma (n=18)
Tuberculosis (n=6)
Sarcoidosis (n=4)
Lymphoma (n=3)
CKD (n=6)
HPT with Vit D toxicity (n=1)
Miscellaneous (n=1)

PTH (pg/ml)
638.1±762.1
8.3±8.7
12.1±7.8
7.6±6.7
9.9±6.4
5.8±3.8
6±6
4.7±2.3
24.6±18.9
443
7.24
Mean±SD are reported

DISCUSSION
HPT in our data remained as one the commonest
cause of hypercalcemia.1 Mean age and female
preponderance of HPT patients in our study are
similar to what reported by others.12,13 Wermer et al
reported the peak incidence of primary
hyperparathyroidism in the seventh decade with most
cases occur in women.13 Primary HPT used to be
presented as bones, stones and groans in the past.
These days the diagnosis is generally biochemical
with high serum calcium and elevated iPTH. Once
biochemical diagnosis is established, localization of
parathyroid adenoma is made by parathyroid
scintigraphy and or by sonography by an experienced
sinologist. Surgical removal of the parathyroid
adenoma is the only curative therapy for primary
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Vitamin-D (ng/ml)
48.8±84
184.8±129.4
92.7±16.1
37.5±19.2
23.6±15.3
18.7±10
23.2±7.8
24.8±6.1
16.1±8.8
150
6.16

Calcium (mg/dl)
12.8±2.2
13.5±1.6
12.5±1.8
13.5±1.8
12.9±1.5
12.4±1.1
13.8±1.7
15.7
12.06±0.9
15.1
14.9

HPT; however, patients above 50 years of age and
mild hypercalcemia and no complications can be
followed.14
VDT has emerged as the second commonest
cause of hypercalcemia in our study. In 25 patients
hypercalcemia can solely be attributed to vitamin
toxicity. The Vitamin-D was administered in the
setting of osteoporosis, related fractures and for
generalized weakness. The amount of Vitamin-D
taken was documented in half of the patients.
Multiple injections of high dose preparations were
the main etiologic factor of VDT. The exact amount
of Vitamin-D taken by these patients could not be
exactly quantified because of the retrospective nature
of the study. In most cases, it was Vitamin-D3
600,000 IU injection given weekly for 6-8 weeks.
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Koul et al reported 10 cases of VDT over 10 years
from Kashmir valley with one patient died because of
concomitant sepsis and multiorgan failure.15 These
patients again had received Vitamin-D in form of
multiple injections and oral sachet for back pain,
radiculopathy,
osteoarthritis
and
generalized
weakness.
Considering this overenthusiastic practice of
Vitamin-D replacement we recently have published a
randomized control trial comparing replacement
strategies with oral and intramuscular doses of
commonly used preparations. Our study showed that
a single dose of 600,000 units of Vitamin-D3
corrected the VDD in 94% of the participants and
multiple injections were not required to correct the
VDD.5
The upper limit of 25-OHD levels has not
been defined. Studies in lifeguards, farmers near the
equator, and sun dwelling hunter gatherers shown
that they maintain blood levels between 40–80 ng/ml
on sun exposure alone.16 Marcus et al has reported a
case of hypercalcemia in a patient with multiple
sclerosis with 25-OHD level of 103ng/ml and no
other identifiable cause of hypercalcemia.17 In our
study, we have identified 11 patients with
unequivocal hypercalcemia, low iPTH and 25-OHD
level ranging from 80–149 pg/ml. We characterized
them as probable Vitamin-D toxicity. Patients in this
group exhibit significant hypercalcemia and similar
hospital course as patients with VDT.
Multiple Myeloma presented as third
important cause of hypercalcemia after HPT and
VDT. This diagnosis is generally sought very
commonly in medical units, and in our study serum
protein electrophoresis was done in most patients.
Other causes of hypercalcemia in our study include
tuberculosis, chronic kidney disease, sarcoidosis and
lymphoma.
The work up of hypercalcemia after the
availability of intact PTH assays has been simplified
into PTH dependent and independent causes. PTH
dependent causes include Primary HPT as the
commonest cause, and rarely prolonged lithium use,
familial hypocalciuric hypercalcemia and tertiary
hyperparathyroidism would result in similar
biochemical profile. To identify a PTH independent
cause remains a challenge when solid tumour
malignancy is not evident. The causes of PTH
independent hypercalcemia commonly include solid
tumour malignancy, multiple myeloma and
granulomatous diseases like tuberculosis, sarcoidosis
and lymphoma.18
Management of acute hypercalcemia is
similar irrespective of the cause; this includes
aggressive hydration with intravenous normal saline,
low dose furosemide once adequate fluid

resuscitation
is achieved, and
intravenous
bisphosphonate. After initial treatment, management
of underlying cause is important.19
The workup or its documentation was
insufficient in 20% of cases to reach to a conclusive
diagnosis; this is because of the retrospective nature
of the study and it is one of the major limitations of
the study.
Another limitation of our study is that we
had not reviewed the management of causes of
hypercalcemia other than VDT in detail. This is
because the causes are varied and requires specific
treatment.

CONCLUSION
Prompt identification and treatment of VDT is very
important because of associated significant morbidity
and mortality, prolonged hospital and costly
investigations. VDT should be kept in mind in cases
of PTH independent hypercalcemia, history of
Vitamin-D intake should be sought and prompt
treatment
with
hydration
and
intravenous
bisphosphonates should be initiated. In one patient
who died because of hospital acquired infections had
a prolonged hospital stay and had undergone multiple
investigations including bone marrow examination
and trephine to evaluate the cause of hypercalcemia.
Physician education regarding replacement
of Vitamin-D is of utmost importance as inadvertent
administration remains the main cause of toxicity.
Physician should adhere to the Endocrine Society20
and Institute of Medicine21 recommendations in
correcting the VDD and in maintenance doses.
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